Aileron Therapeutics Promotes Manuel Aivado to CEO

Manuel Aivado has been appointed president and CEO of Aileron Therapeutics (NASDAQ: [[ticker:ALRN]]). He has also been elected to the Watertown, MA-based company’s board of directors. Aivado, who was Aileron’s chief medical and scientific officer, joined the company in 2014. Aileron started looking for a new CEO in May, after Joseph Yanchik suddenly resigned after 12 years at the company. Aileron’s lead drug, ALRN-6924, is being tested in multiple clinical trials as a treatment for various cancers.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.